60
Participants
Start Date
May 26, 2022
Primary Completion Date
May 2, 2023
Study Completion Date
July 25, 2023
CRD-740
Tablets administered orally.
Placebo
Tablets administered orally.
Cardurion Investigative Site, Tiberias
Cardurion Investigative Site, Norfolk
Cardurion Investigative Site, Greensboro
Cardurion Investigative Site, Atlanta
Cardurion Investigative Site, Haifa
Cardurion Investigative Site, Haifa
Cardurion Investigative Site, Hialeah
Cardurion Investigative Site, Miami
Cardurion Investigative Site, Miami
Cardurion Investigative Site, Tampa
Cardurion Investigative Site, Naples
Cardurion Investigative Site, Alexander City
Cardurion Investigative Site, Birmingham
Cardurion Investigative Site, Fairhope
Cardurion Investigative Site, Tullahoma
Cardurion Investigative Site, Minneapolis
Cardurion Investigative Site, Hazel Crest
Cardurion Investigative Site, Be’er Ya‘aqov
Cardurion Investigative Site, Alexandria
Cardurion Investigative Site, Allen
Cardurion Investigative Site, Rehovot
Cardurion Investigative Site, Torrance
Cardurion Investigative Site, Nahariya
Cardurion Investigative Site, Ashkelon
Cardurion Investigative Site, Winnepeg
Cardurion Investigative Site, High Wycombe
Cardurion Investigative Site, Airdrie
Cardurion Investigative Site, Isleworth
Cardurion Investigative Site, Clydebank
Cardurion Investigative Site, Dundee
Cardurion Investigative Site, Glasgow
Cardurion Investigative Site, Harrow
Cardurion Investigative Site, Newcastle upon Tyne
Cardurion Investigative Site, Stockton-on-Tees
Lead Sponsor
Cardurion Pharmaceuticals, Inc.
INDUSTRY